Using PET/CT imaging to diagnose GLP-1 receptor related diseases
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06725693 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with GLP-1 receptor-related diseases. Participants include adults with suspected or newly diagnosed malignant tumors who are scheduled for an Exendin 4 PET/CT scan. The study measures the uptake of lesions using the maximum standard uptake value (SUVmax) and calculates various diagnostic metrics such as sensitivity and specificity.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with suspected or diagnosed malignant tumors related to GLP-1 receptor activity.
Not a fit: Patients with non-malignant lesions or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of diagnosing GLP-1 receptor-related tumors, leading to better patient management.
How similar studies have performed: While this approach is innovative, similar studies using PET/CT imaging for tumor diagnosis have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Tianjin, Tianjin Municipality
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Qiusong Chen, MD
- Email: qs_c8@hotmail.com
- Phone: +862260362190
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.